Navigation Links
MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results

MARIETTA, Ga., Feb. 23, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that its results for the fourth quarter and full year ended December 31, 2010, and Company guidance will be released after the closing of the market on Monday, March 28, 2011.  The timing of the earnings announcement allows MiMedx time to finalize the required two year audit of its recently acquired subsidiary, Surgical Biologics. The 8K/A filing of the audited financial statements of Surgical Biologics for the fiscal years ended December 31, 2010, and 2009, is due to be filed on Monday, March 14, 2011.

MiMedx Group will host a live broadcast of its 2010 results conference call on Tuesday, March 29, 2011, beginning at 10:30 a.m. Eastern Time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at or at  A 30-day online replay will be available on the Company's website at or at approximately one hour following the conclusion of the live broadcast.

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability.  Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion®, developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures.  MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to accelerate commercialization of our technologies.

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings
2. Native Americans descended from a single ancestral group, DNA study confirms
3. PNAS announces 6 2010 Cozzarelli Prize recipients
4. NIFA announces grants to study the effects of climate change on agricultural and forest production
5. FASEB announces the 2011 Summer Research Conference series: Registration is now open
6. Aware Announces Appointment of New Directors
7. Aware, Inc. Announces Q4 and FY2010 Earnings Conference Call
8. Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement
9. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
10. BTER Foundation announces winners of the William S. Baer Award
11. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
Post Your Comments:
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology: